BioMerieux SA (XPAR:BIM)

€ 98.85 -0.2 (-0.2%) Market Cap: 11.66 Bil Enterprise Value: 11.94 Bil PE Ratio: 28.34 PB Ratio: 3.00 GF Score: 98/100

Half Year 2024 Biomerieux SA Earnings Call Transcript
Sep 05, 2024

€107.3 (+4.17%)

Earnings
Full Year 2023 Biomerieux SA Earnings Call Transcript
Mar 14, 2024

€100.35 (-0.10%)

Earnings
Q3 2023 Biomerieux SA Corporate Sales Call Transcript
Oct 26, 2023
Half Year 2023 Biomerieux SA Earnings Call Transcript
Sep 01, 2023

€94.62 (-1.03%)

Earnings
Biomerieux SA Evolution of Biomerieux's Governance Call Transcript
Jun 14, 2023
Q1 2023 Biomerieux SA Corporate Sales Call Transcript
Apr 27, 2023
Full Year 2022 Biomerieux SA Earnings Call Transcript
Mar 08, 2023

€94.42 (+2.41%)

Earnings
Q3 2022 Biomerieux SA Corporate Sales Call Transcript
Oct 26, 2022
Half Year 2022 Biomerieux SA Earnings Call Transcript
Aug 31, 2022

€91.26 (-5.61%)

Earnings
Q1 2022 Biomerieux SA Business Results Call Transcript
Apr 12, 2022
Full Year 2021 Biomerieux SA Earnings Call Transcript
Mar 02, 2022

€87.56 (-8.68%)

Earnings
Q3 2021 Biomerieux SA Business Review Call Transcript
Oct 21, 2021
Half Year 2021 Biomerieux SA Earnings Call Transcript
Sep 01, 2021

€108 (+4.00%)

Earnings
Q1 2021 Biomerieux SA Business Review Transcript
Apr 27, 2021
Full Year 2020 Biomerieux SA Earnings Call Transcript
Feb 24, 2021

€109.4 (+0.83%)

Earnings
Q3 2020 Biomerieux SA Business Review Call Transcript
Oct 22, 2020
Half Year 2020 Biomerieux SA Earnings Call Transcript
Sep 02, 2020

€122.2 (-2.24%)

Earnings
Q1 2020 Biomerieux SA Corporate Sales Call Transcript
Apr 16, 2020
Full Year 2019 Biomerieux SA Earnings Call Transcript
Feb 26, 2020

€87.25 (-6.53%)

Earnings
Q3 2019 Biomerieux SA Business Review Call Transcript
Oct 22, 2019
Half Year 2019 Biomerieux SA Earnings Call Transcript
Sep 04, 2019

€72.5 (-1.56%)

Earnings
Q1 2019 Biomerieux SA Corporate Sales Call Transcript
Apr 24, 2019
Full Year 2018 Biomerieux SA Earnings Call Transcript
Feb 27, 2019

€73.6 (+6.51%)

Earnings

Full Year 2021 Biomerieux SA Earnings Call Transcript

Mar 02, 2022 / 01:30PM GMT

Release Date Price: €87.56 (-8.68%)

Transcript

Operator

Good day, and welcome to the bioMerieux Full Year 2021 Financial Results. Today's call is being recorded. At this time, I would like to turn the conference over to Franck Admant. Please go ahead.

Franck Admant;rieux S.A.;Director of IR

bioMÃ

©-

Thank you. Good day, everyone, and thank you for joining us to review bioMerieux performance for 2021 and our objective for 2022. Before leaving the floor to Alexandre Merieux, Chairman and CEO; and Guillaume Bouhours, CFO, I will just make a very short introduction to provide you with a couple of information. First of all, our press release was published this morning at 7 a.m. You can find it on the home page of our website.

In addition, note that the slide of this meeting will be available also on the home page, and you can download it shortly after the webcast. From here to the end of the meeting, the webcast and the call will be available in replay on our website.

Now going to the presentation contains after reviewing our 2021 performance and 2022 objectives, where

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.